Aveanna Healthcare Holdings, Inc.
AVAH Nasdaq Services-Home Health Care Services Financials FY2020–FY2026
Revenue
Total sales reported in the income statement.
$2.4B
20.2%
vs prior year
Operating margin
Operating income as a share of revenue.
10.5%
3.6 pts
Net income
Profit after all expenses, interest and tax.
$225M
Free cash flow
Cash from operations minus capital spending.
—
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
19.7%
11.2 pts
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
On $1.26 EPS (TTM)
What Aveanna Healthcare Holdings, Inc. does
No business description yet.
- Legal name
- Aveanna Healthcare Holdings, Inc.
- Fiscal year ends
- January 3, 2026
- Latest annual report
- 10-K · Mar 19, 2026
- Accession · CIK
- 0001193125-26-115851
0001832332
Revenue and margins
Aveanna Healthcare Holdings, Inc. had $2.4B of revenue in fiscal 2026, up 20.2% on the year before.
FY20
Revenue $1.4B
FY21
Revenue $1.5B
FY22
Revenue $1.7B
FY23
Revenue $1.8B
FY24
Revenue $1.9B
FY25
Revenue $2.0B
FY26
Revenue $2.4B
Q3 '24
Revenue $478M
Q4 '24
Revenue $479M
Q1 '25
Revenue $491M
Q2 '25
Revenue $505M
Q3 '25
Revenue $509M
Q4 '25
Revenue $520M
Q1 '26
Revenue $559M
Q2 '26
Revenue $590M
Q3 '26
Revenue $622M
Q4 '26
Revenue $662M
Q1 '27
Revenue $648M
Q2 '27
Revenue $670M
FY20
Gross 30.3%
Operating 2.8%
Net −5.5%
FCF −1.8%
FY21
Gross 30.4%
Operating −0.2%
Net −3.8%
FCF 6.8%
FY22
Gross 32.3%
Operating −2.2%
Net −7.0%
FCF −1.6%
FY23
Gross 30.9%
Operating −35.9%
Net −37.0%
FCF —
FY24
Gross 31.4%
Operating 0.4%
Net −7.1%
FCF —
FY25
Gross 31.4%
Operating 6.9%
Net −0.5%
FCF —
FY26
Gross 33.3%
Operating 10.5%
Net 9.2%
FCF —
Gross
Operating
Net
FCF
Q3 '24
Gross 30.8%
Operating −16.0%
Net −21.4%
FCF —
Q4 '24
Gross 31.0%
Operating 6.1%
Net −5.4%
FCF —
Q1 '25
Gross 29.7%
Operating 4.7%
Net −2.3%
FCF —
Q2 '25
Gross 31.3%
Operating 7.4%
Net 2.8%
FCF —
Q3 '25
Gross 31.4%
Operating 6.7%
Net −8.4%
FCF —
Q4 '25
Gross 33.0%
Operating 8.8%
Net 5.6%
FCF —
Q1 '26
Gross 32.8%
Operating 9.3%
Net 0.9%
FCF —
Q2 '26
Gross 35.8%
Operating 13.6%
Net 4.6%
FCF —
Q3 '26
Gross 32.6%
Operating 8.6%
Net 2.3%
FCF —
Q4 '26
Gross 32.2%
Operating 10.7%
Net 27.0%
FCF —
Q1 '27
Gross 31.7%
Operating 10.7%
Net 6.4%
FCF —
Q2 '27
Gross 32.6%
Operating 11.9%
Net 6.0%
FCF —
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY20
Net income −$76.5M
FY21
Net income −$57.1M
FY22
Net income −$117M
FY23
Net income −$662M
FY24
Net income −$135M
FY25
Net income −$10.9M
FY26
Net income $225M
Q3 '24
Net income −$102M
Q4 '24
Net income −$25.7M
Q1 '25
Net income −$11.2M
Q2 '25
Net income $13.9M
Q3 '25
Net income −$42.8M
Q4 '25
Net income $29.2M
Q1 '26
Net income $5.2M
Q2 '26
Net income $27.0M
Q3 '26
Net income $14.1M
Q4 '26
Net income $179M
Q1 '27
Net income $41.7M
Q2 '27
Net income $40.3M
FY20
Diluted EPS −$0.56
FY21
Diluted EPS −$0.40
FY22
Diluted EPS −$0.69
FY23
Diluted EPS −$3.57
FY24
Diluted EPS −$0.71
FY25
Diluted EPS −$0.06
FY26
Diluted EPS $1.05
Q3 '24
Diluted EPS −$0.54
Q4 '24
Diluted EPS −$0.13
Q1 '25
Diluted EPS −$0.06
Q2 '25
Diluted EPS $0.07
Q3 '25
Diluted EPS −$0.22
Q4 '25
Diluted EPS $0.15
Q1 '26
Diluted EPS $0.03
Q2 '26
Diluted EPS $0.13
Q3 '26
Diluted EPS $0.06
Q4 '26
Diluted EPS $0.83
Q1 '27
Diluted EPS $0.19
Q2 '27
Diluted EPS $0.18
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY20
Return on capital —
Return on equity −28.3%
Return on assets —
FY21
Return on capital −0.2%
Return on equity −21.3%
Return on assets −3.1%
FY22
Return on capital −1.6%
Return on equity −26.0%
Return on assets −5.6%
FY23
Return on capital −40.1%
Return on equity −210.3%
Return on assets −32.7%
FY24
Return on capital 0.6%
Return on equity —
Return on assets −8.1%
FY25
Return on capital 8.5%
Return on equity —
Return on assets −0.7%
FY26
Return on capital 19.7%
Return on equity 634.7%
Return on assets 12.2%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was — in fiscal 2026, — of revenue. Cash from operations minus capital spending.
FY20
Free cash flow −$25.4M
FY21
Free cash flow $101M
FY22
Free cash flow −$27.3M
FY23
Free cash flow —
FY24
Free cash flow —
FY25
Free cash flow —
FY26
Free cash flow —
FY20
Cash from operations −$8.7M
Capital spending $16.6M
FY21
Cash from operations $117M
Capital spending $15.2M
FY22
Cash from operations −$11.4M
Capital spending $16.0M
FY23
Cash from operations −$48.4M
Capital spending —
FY24
Cash from operations $22.7M
Capital spending —
FY25
Cash from operations $32.6M
Capital spending —
FY26
Cash from operations $126M
Capital spending —
Cash from operations
Capital spending
Q3 '24
Cash from operations $28.7M
Capital spending —
Q4 '24
Cash from operations −$3.0M
Capital spending —
Q1 '25
Cash from operations −$12.0M
Capital spending —
Q2 '25
Cash from operations $1.8M
Capital spending —
Q3 '25
Cash from operations $29.4M
Capital spending —
Q4 '25
Cash from operations $13.4M
Capital spending —
Q1 '26
Cash from operations −$8.6M
Capital spending —
Q2 '26
Cash from operations $51.6M
Capital spending —
Q3 '26
Cash from operations $33.2M
Capital spending —
Q4 '26
Cash from operations $49.7M
Capital spending —
Q1 '27
Cash from operations $4.3M
Capital spending —
Q2 '27
Cash from operations $80.9M
Capital spending —
Cash from operations
Capital spending
Dividends, buybacks and share count
Aveanna Healthcare Holdings, Inc. returned — to shareholders in fiscal 2026. The diluted share count rose 11.4%.
FY20
Dividends —
Buybacks —
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
FY26
Dividends —
Buybacks —
Dividends
Buybacks
FY20
Diluted shares 0.14B
FY21
Diluted shares 0.14B
FY22
Diluted shares 0.00B
FY23
Diluted shares 0.19B
FY24
Diluted shares 0.19B
FY25
Diluted shares 0.19B
FY26
Diluted shares 0.21B
Balance sheet
Cash, debt and the ratios that show how comfortably Aveanna Healthcare Holdings, Inc. can carry it.
FY20
Cash —
Debt —
FY21
Cash $137M
Debt $1.2B
FY22
Cash $30.5M
Debt $1.2B
FY23
Cash $19.2M
Debt $1.3B
FY24
Cash $43.9M
Debt $1.3B
FY25
Cash $84.3M
Debt $1.3B
FY26
Cash $193M
Debt $1.3B
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $30.5M | $19.2M | $43.9M | $84.3M | $193M |
| Debt incl. finance leases | $1.2B | $1.3B | $1.3B | $1.3B | $1.3B |
| Net debt / EBITDA | — | — | 56.8x | 7.9x | 4.1x |
| Debt / equity | 1.9x | — | — | — | 6.7x |
| Interest coverage | −0.5x | −6.0x | 0.1x | 0.9x | 1.8x |
| Current ratio | 0.8x | 0.8x | 0.9x | 1.0x | 1.3x |
| Quick ratio | 0.8x | 0.8x | 0.9x | 1.0x | 1.3x |
| Total assets | $2.3B | $1.7B | $1.6B | $1.7B | $2.0B |
| Total liabilities | $1.7B | $1.7B | $1.7B | $1.8B | $1.8B |
| Shareholders' equity | $636M | −$6.3M | −$130M | −$124M | $194M |
| Net debt (− = net cash) | $1.2B | $1.3B | $1.2B | $1.2B | $1.1B |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ |
| Cash from operations is positive | ✕ | ✓ | ✕ | ✕ | ✓ | ✓ | ✓ |
| Return on assets rose | — | — | ✕ | ✕ | ✓ | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✕ |
| Debt fell relative to assets | — | — | ✓ | ✕ | ✕ | ✓ | ✓ |
| Current ratio rose | — | — | ✕ | ✓ | ✓ | ✓ | ✓ |
| Share count didn't rise | — | ✕ | ✓ | ✕ | ✕ | ✕ | ✕ |
| Gross margin rose | — | ✓ | ✓ | ✕ | ✓ | ✕ | ✓ |
| Revenue rose relative to assets | — | — | ✕ | ✓ | ✓ | ✓ | ✕ |
| F-score | — / 3 | — / 5 | 4 / 9 | 3 / 9 | 6 / 9 | 6 / 9 | 6 / 9 |
| Accruals ratio | — | −9.4% | −5.1% | −30.3% | −9.5% | −2.7% | 5.4% |
| Altman Z'' | — | −0.36 | −0.70 | −5.10 | −2.98 | −2.25 | −0.46 |
7 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $1.4B | $1.5B | $1.7B | $1.8B | $1.9B | $2.0B | $2.4B |
| Gross profit | $419M | $455M | $542M | $553M | $595M | $636M | $810M |
| Operating income | $39.0M | −$3.5M | −$36.1M | −$642M | $8.1M | $140M | $256M |
| Interest expense | $92.3M | $83.0M | $68.9M | $108M | $153M | $157M | $140M |
| Pretax income | −$75.0M | −$51.7M | −$114M | −$664M | −$139M | $5.1M | $107M |
| Income tax | $1.5M | $5.3M | $3.5M | −$1.8M | −$4.5M | $16.0M | −$118M |
| Net income | −$76.5M | −$57.1M | −$117M | −$662M | −$135M | −$10.9M | $225M |
| Diluted EPS | −$0.56 | −$0.40 | −$0.69 | −$3.57 | −$0.71 | −$0.06 | $1.05 |
| Diluted shares | 0.14B | 0.14B | 0.00B | 0.19B | 0.19B | 0.19B | 0.21B |
| Cash flow | |||||||
| Cash from operations | −$8.7M | $117M | −$11.4M | −$48.4M | $22.7M | $32.6M | $126M |
| Capital expenditure | $16.6M | $15.2M | $16.0M | — | — | — | — |
| Free cash flow | −$25.4M | $101M | −$27.3M | — | — | — | — |
| Depreciation and amortization | $14.3M | $17.0M | $20.6M | $21.3M | $13.8M | $10.8M | $10.5M |
| Stock-based compensation | $1.9M | $3.3M | $14.4M | $15.9M | $13.2M | $17.5M | $25.1M |
| Acquisitions | $1.0M | $178M | $667M | $2.0M | — | $0.0M | $14.9M |
| Balance sheet | |||||||
| Cash and short-term investments | — | $137M | $30.5M | $19.2M | $43.9M | $84.3M | $193M |
| Total debt | — | $1.2B | $1.2B | $1.3B | $1.3B | $1.3B | $1.3B |
| Current assets | — | $341M | $279M | $270M | $315M | $393M | $560M |
| Current liabilities | — | $260M | $345M | $326M | $355M | $402M | $424M |
| Property and equipment, net | — | $32.7M | $31.4M | $22.8M | $20.5M | $17.4M | $16.7M |
| Goodwill | $1.2B | $1.3B | $1.8B | $1.2B | $1.1B | $1.1B | $1.1B |
| Intangible assets | — | $73.6M | $103M | $95.9M | $94.0M | $89.6M | $92.6M |
| Total assets | — | $1.8B | $2.3B | $1.7B | $1.6B | $1.7B | $2.0B |
| Total liabilities | — | $1.6B | $1.7B | $1.7B | $1.7B | $1.8B | $1.8B |
| Preferred stock | — | — | — | — | — | — | $0.0M |
| Shareholders' equity | $270M | $265M | $636M | −$6.3M | −$130M | −$124M | $194M |
| Margins | |||||||
| Gross margin | 30.3% | 30.4% | 32.3% | 30.9% | 31.4% | 31.4% | 33.3% |
| Operating margin | 2.8% | −0.2% | −2.2% | −35.9% | 0.4% | 6.9% | 10.5% |
| EBITDA margin | 3.8% | 0.9% | −0.9% | −34.7% | 1.2% | 7.4% | 11.0% |
| Net margin | −5.5% | −3.8% | −7.0% | −37.0% | −7.1% | −0.5% | 9.2% |
| FCF margin | −1.8% | 6.8% | −1.6% | — | — | — | — |
| Returns | |||||||
| Return on capital | — | −0.2% | −1.6% | −40.1% | 0.6% | 8.5% | 19.7% |
| Return on capital employed | — | −0.2% | −1.8% | −46.4% | 0.6% | 11.1% | 16.2% |
| Return on equity | −28.3% | −21.3% | −26.0% | −210.3% | — | — | 634.7% |
| Return on assets | — | −3.1% | −5.6% | −32.7% | −8.1% | −0.7% | 12.2% |
| Growth | |||||||
| Revenue growth | — | 8.0% | 12.3% | 6.5% | 6.0% | 6.8% | 20.2% |
| FCF growth | — | — | −126.9% | — | — | — | — |
| Share count change | — | 3.0% | −99.9% | 108,664.9% | 2.4% | 1.5% | 11.4% |
| Financial health | |||||||
| Net debt / EBITDA | — | 76.5x | — | — | 56.8x | 7.9x | 4.1x |
| Debt / equity | — | 4.4x | 1.9x | — | — | — | 6.7x |
| Interest coverage | 0.4x | −0.0x | −0.5x | −6.0x | 0.1x | 0.9x | 1.8x |
| Current ratio | — | 1.3x | 0.8x | 0.8x | 0.9x | 1.0x | 1.3x |
| Quick ratio | — | 1.3x | 0.8x | 0.8x | 0.9x | 1.0x | 1.3x |
| Capital allocation | |||||||
| Capex / revenue | 1.2% | 1.0% | 1.0% | — | — | — | — |
| Stock comp / revenue | 0.1% | 0.2% | 0.9% | 0.9% | 0.7% | 0.9% | 1.0% |
| Quality scores | |||||||
| Piotroski F-score | — | — | 4.0 | 3.0 | 6.0 | 6.0 | 6.0 |
| Altman Z'' | — | −0.4 | −0.7 | −5.1 | −3.0 | −2.3 | −0.5 |
| Accruals ratio | — | −9.4% | −5.1% | −30.3% | −9.5% | −2.7% | 5.4% |
Source: SEC EDGAR XBRL filings (CIK 0001832332). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.